INDEPSO

3.7K posts

INDEPSO banner
INDEPSO

INDEPSO

@indepso

Official account of the 'Indian Network for DEvelopment of Peritoneal Surface Oncology' https://t.co/8IVcZWW19J #Research #réinvention #collaboration

India Katılım Eylül 2019
562 Takip Edilen1.2K Takipçiler
INDEPSO
INDEPSO@indepso·
Across 🇮🇳, women peritoneal malignancy surgeons are leading the fight against peritoneal surface cancers—advancing CRS+HIPEC, research and training the next generation. INDEPSO–SPSOI salutes their skill, courage and compassion this International Women’s Day. @PSOGI_EC @writeslkpushkin @zeebausofi @vivekanandkem @Bhandoria
INDEPSO tweet media
English
1
5
11
179
INDEPSO
INDEPSO@indepso·
Announcing the 3rd Biennial Conference of the Oncology Group of Pune on Peritoneal Surface Malignancy & Gynecologic Oncology. 🗓 17–19 Sept 2026 📍 Pune A focused meeting addressing the complexities and dilemmas in peritoneal surface oncology. Highlights: 🔬 Pre-conference Cadaveric Workshop on Cytoreductive Surgery & Peritonectomy 🧠 Didactic lectures & panel discussions 🔎 Live pathology workshop 🌍 Stellar international & national faculty Featuring renowned international experts including Prof. @PSugarbaker , Prof. @glehenolivier , Prof. Artem Stepanyan & Prof. Lana Bijelic. Join us in Pune to exchange ideas, debate dilemmas, and advance care in peritoneal surface malignancy. @writeslkpushkin @PSOGI_EC @IASO_IJSOonline @sukumar_vivek @MufaddalKazi @avanishsaklani @zeebausofi #CRS #HIPEC #SurgicalOncology #GynecOnc #PeritonealSurfaceMalignancy
INDEPSO tweet media
English
0
6
11
284
INDEPSO
INDEPSO@indepso·
Good quality periop care is the backbone of a 💪 peritoneal malignancy prog. If you are a surgeon, anasthetist, intensivist or clinician involved in looking after such patients, you cant miss this 👇 ICU Mx in CRS HIPEC 2000-2100 hrs IST. Join and share
INDEPSO tweet media
English
1
7
8
358
INDEPSO retweetledi
ESGO
ESGO@ESGO_society·
Published today in @JAMA_current : ESGO Consensus statements on opportunistic salpingectomy for the prevention of tubo-ovarian carcinoma 🗞️🤓🙌 Read it here 👉jamanetwork.com/journals/jama/… Kudos to the authors!
ESGO tweet media
English
0
6
7
374
INDEPSO
INDEPSO@indepso·
3️⃣ — Response (biology revealed) Mezhir et al. (Ann Surg 2010) showed that CY+ gastric cancer patients who clear cytology after chemotherapy live significantly longer. Response isn’t separate from biology — it is biology under treatment pressure. #GastricCancer #HIPEC
English
1
2
3
248
INDEPSO
INDEPSO@indepso·
Gastric Cancer with Synchronous Peritoneal Metastasis (GCPM) Why does CRS HIPEC fail repeatedly? What are we doing wrong? Who is the right patient? (Biology vs burden vs response) 👉Unanswered question: ♦️Can we reliably identify a subgroup of GCPM patients who truly benefit from locoregional therapy (CRS/HIPEC)? Why this is unresolved -PCI cut-offs (≤6–7) are crude surrogates for biology. -PERISCOPE II showed no OS benefit even in low PCI, suggesting biology dominates. -CY+ (PCI 0) patients behave heterogeneously — some convert and do well, others progress rapidly. In GCPM, biology and response aren’t competing concepts. Response is biology under stress. PCI defines what we can resect — not who will benefit. #OncoTwitter #GastricCancer #HIPEC #SurgicalOncology 👉Key gaps 1. Molecular predictors (diffuse type, signet ring, EMT signatures) 2. Response-based selection (post-chemo CY conversion, ctDNA clearance) 3. Integration of dynamic response markers rather than baseline PCI alone 📌 This is the single biggest barrier to progress. 🧵Follow thread for more: @zeebausofi @IASO_IJSOonline @vivekanandkem @PSOGI_EC @PSugarbaker @sukumar_vivek
English
1
2
6
289
INDEPSO
INDEPSO@indepso·
Save the date 23/01/2026 Friday Live in conversation with the stalwarts in #PSM and #pseudomyxoma @zeebausofi @vivekanandkem @sukumar_vivek @Snioncosurgeon1 @IASO_IJSOonline
Peritoneal Surface Oncology Group International@PSOGI_EC

💥 💣 Starting 2026 with a 💣 💣 💣 💥 CASE OF THE MONTH #49 #PSOGICASE Cytoreductive surgery for EXTENSIVE pseudomyxoma peritonei: Critical intraoperative decisions and hashtag#Troubleshooting Moderator: @LanaBijelicMD ⭐ ⭐ Expert panel ⭐ ⭐ #MarcelloDeraco #BrendanMoran @DrFloresAyala @SafakGuel and @PSugarbaker 📅 23rd Jan, Friday ⏰ 4.00 pm CET ⏰ 10.00 am EST ⏰ 9.00 am Mexico ⏰ 11.00 am Brazil ⏰ 6.00 pm Middle east #PMP #PseudomyxomaPeritonei never ceases to challenge and surprise a surgeon. No matter how many interesting cases have been discussed, there is always something 🆕 in the next one! 🟠 Change in surgical plan- CC-0/1 to maximum tumor debulking 🔴 Change in surgical plan- one stage to two stage 🟡 Where to begin and which region to address first? 🔵 CC-1 with total gastrectomy versus CC-2 with subtotal gastrectomy 🟣 Preservation of short colonic segment versus total colectomy 🟢 Assessment of bowel vascularity 🟤 Extensive diaphragm and Glisson's capsule involvement ⚫ Management of intraoperative haemorrhage Join the zoom meeting Join Zoom Meeting us06web.zoom.us/j/83669468081?… Meeting ID: 836 6946 8081 Passcode: 918837 Or watch it live on #YouTube @PSOGI_EC" target="_blank" rel="nofollow noopener">youtube.com/@PSOGI_EC @FarazKh65499316 @indepso @vivekanandkem @CNevrez @ArasEmreCanda @SWexner @polat066 @CelestinoGutirr

English
0
3
6
301
INDEPSO retweetledi
MV Chandrakanth
MV Chandrakanth@ChandrakanthMv·
• MSI-H CRC isn’t uniform • Early-onset → Lynch-like biology (MSH2/MSH6, KRAS/APC/PI3K, CMS3/4) + better IO responses • Late-onset → Sporadic (MLH1-methylation/BRAF) + less IO benefit • Etiology matters #Oncology #CRC #MSIH #Immunotherapy #PrecisionOncology
MV Chandrakanth tweet media
English
2
32
70
3.1K
INDEPSO retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
SCOT 2026 – Final OS analysis 🔎In >6,000 pts with stage II (high-risk) and stage III CRC, long-term follow-up (~10 years) shows no OS difference between 3 vs 6 months of adjuvant oxaliplatin-fluoropyrimidine. 5-yr OS: 82.4% vs 82.4% (HR 0.96) 💡Outcomes were regimen-dependent: • CAPOX: 3 months was non-inferior to 6 months • FOLFOX: non-inferiority was not statistically confirmed Risk-based analysis in stage III: • Low-risk (T3N1): similar OS with 3 vs 6 months • High-risk (T4 and/or N2): small absolute OS differences! 📌Rectal cancer (unique to SCOT within IDEA): 3 months achieved OS comparable to 6 months, particularly with CAPOX. 💬In summary, for the majority of patients, 3 months of treatment is sufficient. ascopubs.org/doi/10.1200/JC…
Yakup Ergün tweet mediaYakup Ergün tweet mediaYakup Ergün tweet media
English
3
51
97
12.1K
INDEPSO retweetledi
Myriam Chalabi
Myriam Chalabi@MyriamChalabi·
Excited, happy and proud to share our @Nature publication on neoadjuvant ICB in pMMR colon cancer; #NICHE! We provide validation of previous clinical results, plus extensive and comprehensive analyses of Overdue tweetorial below❗️ nature.com/articles/s4158…
English
2
52
159
18.6K
INDEPSO
INDEPSO@indepso·
Here’s the year end review of INDEPSO More to look forward to in 2026 Wishing all a very happy new year.
English
0
1
5
111

Keşfet

@AnnSurgOncol @writeslkpushkin @glehenolivier @PSOGI_EC @cirugiacancer @aecirujanos @zeebausofi @vivekanandkem